Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.

8 Jan 2023

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.

3 Jan 2023

What are the long-term outcomes of critical COVID-19 patients?

Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.

21 Dec 2022

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants

Researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody in the treatment of high-risk SARS-CoV-2 Omicron variant-infected patients.

13 Dec 2022

The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans

Researchers evaluated the effectiveness of SARS-CoV-2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America.

13 Dec 2022

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Researchers evaluated the incidence of COVID-19 rebound among SARS-CoV-2 -positive patients treated with oral antiviral drugs such as nirmatrelvir-ritonavir combination and molnupiravir.

12 Dec 2022

Exploring clinical characteristics and outcomes of hospitalized COVID-19 patients

Researchers described the clinical characteristics and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) in the Netherlands.

24 Nov 2022

What is the prevalence of contraindications to Paxlovid among hospitalized COVID-19 patients?

Researchers examined the prevalence of contraindications to nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients.

17 Nov 2022

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

In a recent study published in the journal JAMA Network, researchers in the United States investigated factors that restricted the use of antivirals directed at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) between January and February 2022.

16 Nov 2022

Short-term outcomes in pregnant patients with COVID-19 who received nirmatrelvir–ritonavir treatment

Researchers investigated the short-term outcomes of treating pregnant patients exhibiting mild to moderate symptoms of COVID-19 with Paxlovid, which is a combination of the antivirals nirmatrelvir and ritonavir.

15 Nov 2022

Study shows consistent efficacy of Paxlovid regardless of age, number of vaccinations, comorbidities

In a recent study posted to the medRxiv* preprint server, researchers in Canada evaluated nirmatrelvir and ritonavir (Paxlovid) effectiveness against severe coronavirus disease 2019 (COVID-19) during the dominance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and Omicron sub-VOCs in Canada.

7 Nov 2022

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.

6 Nov 2022

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

2 Nov 2022

Cohort study determines how often COVID-19 symptoms recurred

Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.

1 Nov 2022

How does COVID-19 and its treatment affect testicular function?

Researchers summarized available information related to the reproductive effects of COVID-19 in men.

23 Oct 2022

Multiomics analysis identifies immunobiomarkers for COVID-19 severity in outpatients

In a recent study published in the journal eLife, researchers showed the utility of machine-learning models in identifying early immune signatures, which could reliably predict clinical and immunological outcomes in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected outpatients.

20 Oct 2022